COVID-19 and Its Impact on Upper Gastrointestinal (GI) Cancer Management

Cancers

Borzoueh Mohammadi¹  Mesel Veli²  Khurum Khan²  Shalini Fernando²  Andrew Millar² 

[1] Department of GI Oncology, University College Hospital, 235 Euston Road, Bloomsbury, London NW1 2BU, UK;North Middlesex University Hospital, Sterling Way, London N181QX, UK;

关键词: gastrointestinal;    cancer;    coronavirus;    endosocopy;    COVID-19;    SARS-Cov-2;   

DOI  :  10.3390/cancers13030397

来源: DOAJ

【 摘 要 】

Coronavirus disease 2019 (COVID-19), caused by the novel, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has left dramatic footprints on human health and economy. Cancer, whilst not an infective disease, is prevalent in epidemic proportions and cannot be pretermitted due to the impact of COVID-19. As we emanate from the second national lockdown in the UK with mixed feelings of hope and despair—due to vaccination and new COVID-19 variant, respectively—we reflect on the impact of the first wave on the provision on diagnosis and management of with upper gastrointestinal (UGI) cancers. This review provides a critical analysis of available literature on COVID-19 and its impact on cancer management in general and that of UGI cancers in particular.

【 授权许可】

Unknown